• Je něco špatně v tomto záznamu ?

Efficacy of sunitinib in patients with metastatic or unresectable renal cell carcinoma and renal insufficiency

A. Poprach, Z. Bortlicek, B. Melichar, R. Lakomy, M. Svoboda, I. Kiss, M. Zemanova, O. Fiala, K. Kubackova, O. Coufal, T. Pavlik, L. Dusek, R. Vyzula, T. Buchler,

. 2015 ; 51 (4) : 507-13.

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc15022870

AIM: The aim of this retrospective, registry-based study was to analyse treatment outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib and renal insufficiency (RI). METHODS: The cohort included 790 patients treated with sunitinib between 2006 and 2013. At the start of sunitinib therapy 22, 234, and 534 patients had severe (glomerular filtration rate [GFR] <30ml/min/1.73m(2)), moderate (GFR 30-60 ml/min/1.73m(2)) or mild RI/normal renal function (GFR >60ml/min/1.73m(2)), respectively. RESULTS: For the three groups defined above, median progression-free survival (PFS) (95% confidence interval [CI]) was 5.3 months (0.1-18.5), 8.1 months (6.2-9.9) and 11.3 months (9.4-13.2) (p=0.244), and median overall survival (OS) was 26.3 months (1.2-51.4), 21.2 months (13.2-29.1) and 26.3 months (22.6-29.9) (p=0.443), respectively. The disease control rates were 45.5%, 56.4% and 59.2%, respectively (p=0.374). No unexpected toxicity was reported in the patients with RI, but the treatment was more frequently discontinued because of adverse events and the duration of therapy was significantly shorter in these patients (p=0.007). CONCLUSIONS: Duration of first-line targeted treatment for mRCC was significantly shorter for patients with RI, and may have translated into a trend to shorter PFS. These results highlight the need for optimal management of side-effects in patients with mRCC and RI.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15022870
003      
CZ-PrNML
005      
20170118080756.0
007      
ta
008      
150709s2015 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ejca.2014.12.010 $2 doi
035    __
$a (PubMed)25577735
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Poprach, Alexandr $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute and Faculty of Medicine, Masaryk University, Zluty kopec 7, 656 53 Brno, Czech Republic.
245    10
$a Efficacy of sunitinib in patients with metastatic or unresectable renal cell carcinoma and renal insufficiency / $c A. Poprach, Z. Bortlicek, B. Melichar, R. Lakomy, M. Svoboda, I. Kiss, M. Zemanova, O. Fiala, K. Kubackova, O. Coufal, T. Pavlik, L. Dusek, R. Vyzula, T. Buchler,
520    9_
$a AIM: The aim of this retrospective, registry-based study was to analyse treatment outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib and renal insufficiency (RI). METHODS: The cohort included 790 patients treated with sunitinib between 2006 and 2013. At the start of sunitinib therapy 22, 234, and 534 patients had severe (glomerular filtration rate [GFR] <30ml/min/1.73m(2)), moderate (GFR 30-60 ml/min/1.73m(2)) or mild RI/normal renal function (GFR >60ml/min/1.73m(2)), respectively. RESULTS: For the three groups defined above, median progression-free survival (PFS) (95% confidence interval [CI]) was 5.3 months (0.1-18.5), 8.1 months (6.2-9.9) and 11.3 months (9.4-13.2) (p=0.244), and median overall survival (OS) was 26.3 months (1.2-51.4), 21.2 months (13.2-29.1) and 26.3 months (22.6-29.9) (p=0.443), respectively. The disease control rates were 45.5%, 56.4% and 59.2%, respectively (p=0.374). No unexpected toxicity was reported in the patients with RI, but the treatment was more frequently discontinued because of adverse events and the duration of therapy was significantly shorter in these patients (p=0.007). CONCLUSIONS: Duration of first-line targeted treatment for mRCC was significantly shorter for patients with RI, and may have translated into a trend to shorter PFS. These results highlight the need for optimal management of side-effects in patients with mRCC and RI.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a protinádorové látky $x terapeutické užití $7 D000970
650    _2
$a karcinom z renálních buněk $x farmakoterapie $x patofyziologie $7 D002292
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a hodnoty glomerulární filtrace $7 D005919
650    _2
$a lidé $7 D006801
650    _2
$a indoly $x terapeutické užití $7 D007211
650    _2
$a nádory ledvin $x farmakoterapie $x patofyziologie $7 D007680
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a metastázy nádorů $7 D009362
650    _2
$a pyrroly $x terapeutické užití $7 D011758
650    _2
$a renální insuficience $x patofyziologie $7 D051437
650    _2
$a retrospektivní studie $7 D012189
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Bortlicek, Zbynek $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Kamenice 126/3, 625 00 Brno, Czech Republic.
700    1_
$a Melichar, Bohuslav $u Department of Oncology, Palacky University Medical School and Teaching Hospital, I.P. Pavlova 6, 775 20 Olomouc, Czech Republic.
700    1_
$a Lakomy, Radek $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute and Faculty of Medicine, Masaryk University, Zluty kopec 7, 656 53 Brno, Czech Republic.
700    1_
$a Svoboda, Marek $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute and Faculty of Medicine, Masaryk University, Zluty kopec 7, 656 53 Brno, Czech Republic.
700    1_
$a Kiss, Igor $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute and Faculty of Medicine, Masaryk University, Zluty kopec 7, 656 53 Brno, Czech Republic.
700    1_
$a Zemanova, Milada $u Department of Oncology, General University Hospital and Charles University First Faculty of Medicine, U Nemocnice 499/2, 128 08 Prague, Czech Republic.
700    1_
$a Fiala, Ondřej $u Department of Oncology, University Hospital, Svobody 80, 304 60 Pilsen, Czech Republic. $7 xx0209889
700    1_
$a Kubackova, Katerina $u Department of Oncology, Motol University Hospital and Charles University Second Faculty of Medicine,V uvalu 84/1, 150 00 Prague, Czech Republic.
700    1_
$a Coufal, Oldrich $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute and Faculty of Medicine, Masaryk University, Zluty kopec 7, 656 53 Brno, Czech Republic.
700    1_
$a Pavlik, Tomas $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Kamenice 126/3, 625 00 Brno, Czech Republic.
700    1_
$a Dusek, Ladislav $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Kamenice 126/3, 625 00 Brno, Czech Republic.
700    1_
$a Vyzula, Rostislav $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute and Faculty of Medicine, Masaryk University, Zluty kopec 7, 656 53 Brno, Czech Republic.
700    1_
$a Buchler, Tomas $u Department of Oncology and First Faculty of Medicine, Thomayer Hospital and Charles University, Videnska 800, 140 59 Prague, Czech Republic. Electronic address: tomas.buchler@ftn.cz.
773    0_
$w MED00009626 $t European journal of cancer (Oxford, England 1990) $x 1879-0852 $g Roč. 51, č. 4 (2015), s. 507-13
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25577735 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150709 $b ABA008
991    __
$a 20170118080903 $b ABA008
999    __
$a ok $b bmc $g 1083209 $s 905863
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 51 $c 4 $d 507-13 $i 1879-0852 $m European journal of cancer $n Eur J Cancer $x MED00009626
LZP    __
$a Pubmed-20150709

Najít záznam

Citační ukazatele

Možnosti archivace